摘要
目的探讨培美曲塞联合顺铂治疗晚期肺腺癌的临床疗效及不良反应。方法将48例晚期肺腺癌患者随机分为2组,观察组24例采用培美曲塞联合顺铂一线治疗,对照组24例采用多烯紫杉醇治疗,治疗2个周期后评价疗效,并观察不良反应。结果观察组总有效率及临床获益率高于对照组,但2组差异无统计学意义;治疗后观察组体质量和卡氏评分均较治疗前显著升高,并且显著高于对照组;2组患者治疗后血清中癌胚抗原125(CA125)和癌胚抗原(CEA)含量均显著下降,且观察组显著低于对照组;观察组血液毒性、胃肠道反应及脱发发生率显著低于对照组。结论培美曲塞联合顺铂治疗晚期肺癌患者能够显著提高患者的生活质量,不良反应较轻,值得在临床推广使用。
Objective To evaluate the efficacy and adverse reactions of pemetrexed com- bined with cisplatin in patients with advanced lung cancer. Methods Forty-eight patients with ad- vanced lung cancer were randomly divided into two groups. The observation group （ n = 24） re- ceived pemetrexed combined with cisplatin, and the control group （ n = 24） received docetaxel. The efficacy and adverse reactions were evaluated after two cycles. Results The overall response and clinical benefit rate in the observation group were higher than that in the control group, but there was no significant difference. The body mass and KPS scoring in the observation group after treat- ment were obviously higher, and they were obviously higher than that in the control group. The levels of CA125 and CEA significantly decreased in both groups after treatment, while the observa- tion group showed significantly lower levels than the control group. The incidence of blood toxicity, gastrointestinal reaction and alopecia in the observation group were obviously lower than that in the control group. Conclusion Pemetrexed in combination with cisplatin for advanced lung cancer pa- tients can significantly improve the quality of life, decrease incidence of adverse reactions. It is wor- thy of clinical application.
出处
《实用临床医药杂志》
CAS
2012年第19期91-93,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11220172)
关键词
培美曲塞
顺铂
肺癌
pemetrexed
cisplatin
lung cancer
